Faculty

Back to Index
Kevin Kelly, MD
Associate Professor of Clinical Medicine
Medicine
NOR 1441 Eastlake Ave Health Sciences Campus Los Angeles
+1 323 865 3828

Overview

Dr. Kelly is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.

Dr. Kelly earned his medical degree and PhD from University College Cork. He then went on to complete an Advanced Drug Development Clinical Fellowship at The University of Texas Health Science Center.

Awards

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Travel Award, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Travel Award, 2009

National Cancer Institute: Cancer Clinical Investigator Team Leadership Award, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: ct_data, 2009

National Cancer Institute: ct_data, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: ct_data, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: has faculty rank, 2009

National Cancer Institute: has faculty rank, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: has faculty rank, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: ORNG Application Instance for Person, 2009

National Cancer Institute: ORNG Application Instance for Person, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: ORNG Application Instance for Person, 2011

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: full name, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: full name, 2009

National Cancer Institute: full name, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Kelly, Kevin, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Kelly, Kevin, 2011

National Cancer Institute: Kelly, Kevin, 2016

National Cancer Institute: ORNG Application Instance Data value, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: ORNG Application Instance Data value, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: ORNG Application Instance Data value, 2011

National Cancer Institute: person in primary position, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: person in primary position, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: person in primary position, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: is primary position, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: is primary position, 2011

National Cancer Institute: is primary position, 2016

National Cancer Institute: last name, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: last name, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: last name, 2009

National Cancer Institute: ORNG Application URL, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: ORNG Application URL, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: ORNG Application URL, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: HR job title, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: HR job title, 2011

National Cancer Institute: HR job title, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Department, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Department, 2011

National Cancer Institute: Department, 2016

National Cancer Institute: sort order, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: sort order, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: sort order, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Organization, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Organization, 2009

National Cancer Institute: Organization, 2016

National Cancer Institute: Person, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Person, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Person, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: ClinicalTrials, 2011

National Cancer Institute: ClinicalTrials, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: ClinicalTrials, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: email address, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: email address, 2009

National Cancer Institute: email address, 2016

National Cancer Institute: start date, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: start date, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: start date, 2011

National Cancer Institute: award conferred by, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: award conferred by, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: award conferred by, 2009

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Person ID, 2009

National Cancer Institute: Person ID, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: has ORNG Application Instance Data, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: has ORNG Application Instance Data, 2009

National Cancer Institute: has ORNG Application Instance Data, 2016

National Cancer Institute: Keck School of Medicine of USC, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Keck School of Medicine of USC, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Keck School of Medicine of USC, 2011

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Associate Professor, 2011

National Cancer Institute: Associate Professor, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Associate Professor, 2009

National Cancer Institute: label, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: label, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: label, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: position in organization, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: position in organization, 2011

National Cancer Institute: position in organization, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Faculty Rank, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Faculty Rank, 2011

National Cancer Institute: Faculty Rank, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: award or honor for, 2009

National Cancer Institute: award or honor for, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: award or honor for, 2011

National Cancer Institute: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^10061-120, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^10061-120, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^10061-120, 2009

ASCO/AACR Workshop on Methods in Clinical Cancer Research: preferred title, 2009

National Cancer Institute: preferred title, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: preferred title, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: first name, 2009

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: first name, 2011

National Cancer Institute: first name, 2016

National Cancer Institute: Agent, 2016

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Agent, 2009

National Cancer Institute: Medicine, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Medicine, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Medicine, 2009

ASCO/AACR Workshop on Methods in Clinical Cancer Research: type, 2009

National Cancer Institute: type, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: type, 2011

National Cancer Institute: Award or Honor Receipt, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Award or Honor Receipt, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Award or Honor Receipt, 2009

ASCO/AACR Workshop on Methods in Clinical Cancer Research: photo, 2009

National Cancer Institute: photo, 2016

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: photo, 2011

Publications

Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clin Cancer Res. 2017 Mar 01; 23(5):1186-1192. View in: PubMed

Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol. 2016 Nov; 78(5):929-939. View in: PubMed

Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016 Jun; 29(6):570-81. View in: PubMed

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016 May; 17(5):622-31. View in: PubMed

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45. View in: PubMed

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 1; 22(1):34-43. View in: PubMed

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 1; 6(38):41275-89. View in: PubMed

The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res. 2015 Jan 15; 21(2):439-47. View in: PubMed

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014 Nov; 167(3):366-75. View in: PubMed

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014 Jun; 32(3):489-99. View in: PubMed

A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy. 2014 May; 34(5):440-51. View in: PubMed

An evaluation of elderly patients (=70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011. J Geriatr Oncol. 2014 Jan; 5(1):65-70. View in: PubMed

Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014; 8(1):1-20. View in: PubMed

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3577-90. View in: PubMed

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012 Dec 1; 131(11):2693-703. View in: PubMed

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct; 21(10):1563-73. View in: PubMed

Autophagy as a target for cancer therapy: new developments. Cancer Manag Res. 2012; 4:357-65. View in: PubMed

Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol. 2012 Jan; 156(1):129-32. View in: PubMed

The Pim kinases: new targets for drug development. Curr Drug Targets. 2011 Dec; 12(14):2059-66. View in: PubMed

Targeting aurora kinases in cancer treatment. Curr Drug Targets. 2011 Dec; 12(14):2067-78. View in: PubMed

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011 Oct; 15(10):2057-70. View in: PubMed

Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011 Mar; 6(1):53-61. View in: PubMed

Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011 Mar; 6(1):17-27. View in: PubMed

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25; 286(8):6602-13. View in: PubMed

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010 Oct; 14(10):2448-59. View in: PubMed

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010 May 6; 115(18):3796-800. View in: PubMed

Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010 Jan; 46(1):33-40. View in: PubMed

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010 Jan 1; 16(1):141-53. View in: PubMed

Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009 Jul; 9(7):817-30. View in: PubMed

Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2009 Jun; 14(2):311-28. View in: PubMed

Powered bySC CTSI